Genmab — September 2023
-
Therapeutic Potential of Tisotumab Vedotin in the Treatment of Recurrent or Metastatic Cervical Cancer: A Short Report on the Emerging Data https://www.dovepress.com/therapeutic-potential-of-tisotumab-vedotin-in-the-treatment-of-recurre-peer-reviewed-fulltext-article-CMAR
-
Second-Line Tisotumab Vedotin Shows Durability in Cervical Cancer https://www.targetedonc.com/view/second-line-tisotumab-vedotin-shows-durability-in-cervical-cancer
-
20 November 2023 at Panum, UCPH, Keynote speaker Jan G. J. van de Winkel https://bridge.ku.dk/alumni-network/alumni-event/ may be of interest to some locals
-
I am not sure if this will be the first data outside of cervical cancer? these are the arms with pembrolizumab and
carboplatin. https://classic.clinicaltrials.gov/ct2/show/NCT03485209 -
Lidt tankevækkende...det har været bedre at have penge i banken....;-)
-
Genmab i år -13% bankbogen +2,75%:-)
-
Frem og tilbage her i huset er noget HELT andet:-D
-
Jeg er mere glad for at kigge på min bankbog end på Genmab ihvertfald pt:-)
-CD40x4-1BB), exhibits in vivo antitumor activity and peripheral immune modulation
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind